Besivance besifloxacin ophthalmic solution regulatory update

Bausch & Lomb said FDA approved an NDA for Besivance besifloxacin 0.06% ophthalmic suspension to treat bacterial conjunctivitis. An FDA advisory committee voted unanimously to recommend approval of th...